NETRF, in partnership with the North American Neuroendocrine Tumor Society (NANETS), is pleased to announce that Iacovos Michael, PhD, Scientist at Sunnybrook Research Institute and
Positive results are reported from the Phase 3 CABINET trial evaluating the drug cabozantinib in advanced neuroendocrine tumors. Interim data shows significant improvement in progression-free
In December 2022, four neighborhood girls from Libertyville, Il, gathered to support cancer research for the Neuroendocrine Tumor Research Foundation with a “Cookies for Cancer”
NETRF’s impact on neuroendocrine cancer research was evident at the 20th Annual European Neuroendocrine Tumor Society (ENETS) Conference, held March 22-24 in Vienna. The ENETS
A key tenet of NETRF’s mission is to help NET patients navigate the challenges of living with NET cancer. Participating in a clinical trial can
We are very grateful to Buckeye Cable Arts Network for allowing us to promote and share this wonderful story reporter Fayth Atkins produced about NET
BE HEARD: Share your story with staff of the FDA about your experience or your loved one’s living with #CarcinoidSyndrome (CS). #FDA’s Patient Affairs and NORD are hosting
NET patient, oncologist, and NETRF Board Member Mark Lewis, MD, is a native Scotsman who moved to Austin, TX as a young man when his
The Cancer Moonshot’s success relies on ‘collaborative oncology.’ Just last month, the Neuroendocrine Tumor Research Foundation (NETRF) hosted our first in-person/hybrid research symposium since going
We introduced you to Lilly Pearce back in 2019, when she was about halfway through her senior year of high school and six months post-operation
